Analytical Data
-
Gene name
CT45A1
- Application
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q5HYN5
-
Expression Region
Met1~Ile189
-
Molecular Weight
27kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CT45A1, a member of the Cancer/Testis Antigen (CTA) family, has garnered significant attention in cancer research due to its restricted expression profile. Unlike many antigens that are broadly expressed in healthy tissues, CT45A1 is predominantly found in testicular germ cells and various cancer types, particularly melanoma, bladder cancer, and certain types of leukemia. This selective expression pattern makes CT45A1 an appealing target for cancer immunotherapy, as it may elicit an immune response with minimal off-target effects. Recent studies suggest that the presence of CT45A1 can be correlated with tumor progression and patient prognosis, indicating its potential role as a biomarkers. Additionally, the development of CT45A1-based vaccines and adoptive T-cell therapies is being explored, aiming to harness the immune system to specifically target and eliminate cancer cells expressing this antigen. Overall, the research on CT45A1 not only enhances the understanding of tumor immunology but also paves the way for innovative therapeutic strategies in cancer treatment.
